Pancreatic Cancer Research

ResearcherCentral South UniversityActive in the last 2 years

Dongjie Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9992-5019; OpenAlex author ID A5100752824. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers

Papers 8

  1. TFAP2A enhances tumor stemness and promotes metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.113060↗
  2. Identification of a Novel Small Molecule STING Agonist Reshaping the Immunomicroenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/ijbs.107837↗
  3. IGF2BP2-related modification patterns in pancreatic cancer: A machine learning-driven approach towards personalized treatment. Co-author DOI 10.1016/j.heliyon.2024.e28243↗
  4. Machine learning algorithm integrates bulk and single-cell transcriptome sequencing to reveal immune-related personalized therapy prediction features for pancr… Co-author DOI 10.18632/aging.205293↗
  5. Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multice… Co-author DOI 10.7150/thno.84978↗
  6. Ferroptosis-Related IncRNAs Are Prognostic Biomarker of Overall Survival in Pancreatic Cancer Patients. Co-author DOI 10.3389/fcell.2022.819724↗
  7. Interplay of four types of RNA modification writers revealed distinct tumor microenvironment and biological characteristics in pancreatic cancer. First author DOI 10.3389/fimmu.2022.1031184↗
  8. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.728062↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Longjun Zang · 6 shared papers, 2021–2024 · strength 1.04
  2. Wenzhe Gao · 4 shared papers, 2021–2024 · strength 0.70
  3. Hongwei Zhu · 4 shared papers, 2021–2024 · strength 0.70
  4. Yizhi Cao · 3 shared papers, 2023–2025 · strength 0.57
  5. Lingxi Jiang · 3 shared papers, 2023–2025 · strength 0.57
  6. Xiao Yu · 2 shared papers, 2022–2024 · strength 0.37
  7. Shuyu Zhai · 2 shared papers, 2023–2025 · strength 0.36
  8. Chenghong Peng · 2 shared papers, 2023–2025 · strength 0.36
  9. Jiayu Lin · 1 shared paper, 2025 · strength 0.22
  10. Yihao Liu · 1 shared paper, 2025 · strength 0.22
  11. Yang Liu · 1 shared paper, 2025 · strength 0.22
  12. Pengyi Liu · 1 shared paper, 2025 · strength 0.22
  13. Baiyong Shen · 1 shared paper, 2025 · strength 0.22
  14. Kexian Li · 1 shared paper, 2025 · strength 0.21
  15. Xiaomei Tang · 1 shared paper, 2025 · strength 0.21
  16. Meilin Xue · 1 shared paper, 2025 · strength 0.21
  17. Jiaxin Luo · 1 shared paper, 2025 · strength 0.21
  18. Qingwang Miao · 1 shared paper, 2023 · strength 0.19
  19. Xiaodong Tian · 1 shared paper, 2023 · strength 0.19
  20. Xiao Yu · 1 shared paper, 2022 · strength 0.17
  21. Hui Huang · 1 shared paper, 2021 · strength 0.16
  22. Xiao Yu · 1 shared paper, 2021 · strength 0.16
  23. Shulin Zhao · 1 shared paper, 2023 · strength 0.14
  24. Haoyu Tang · 1 shared paper, 2023 · strength 0.14
  25. Weishen Wang · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.